SCHEMBL2718299

SCHEMBL2718299

CCC(=O)Nc1cc(C(=O)NCc2cc(C(F)(F)F)cc(C(F)(F)F)c2)ccn1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MLYCD O95822 1/20 0.52
HPGD P15428 6/20 0.51
ALDH1A1 P00352 6/20 0.51
KDM4E B2RXH2 4/20 0.51
CYP1A2 P05177 2/20 0.51
CYP2D6 P10635 2/20 0.51
CYP2C19 P33261 2/20 0.51
CYP3A4 P08684 1/20 0.51
CYP2C9 P11712 1/20 0.51
TACR1 P25103 4/20 0.49
KDM1A O60341 1/20 0.47
HDAC1 Q13547 1/20 0.47
ROS1 P08922 1/20 0.47
GAA P10253 2/20 0.45
NPSR1 Q6W5P4 1/20 0.45
MTOR P42345 1/20 0.44
SCN9A Q15858 1/20 0.44
LMNA P02545 1/20 0.44
HTT P42858 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2715156 0.94 NAMPT (0.49) MLYCDHPGDALDH1A1KDM4ECYP1A2
SCHEMBL2714261 0.90 MLYCD (0.56) MLYCDALDH1A1CYP1A2CYP2D6CYP2C19
SCHEMBL2714653 0.89 MLYCD (0.54) MLYCDHPGDALDH1A1KDM4ECYP1A2
SCHEMBL2715403 0.86 SCN9A (0.59) MLYCDHPGDALDH1A1KDM4ECYP1A2
SCHEMBL2718889 0.83 RIPK1 (0.44) KDM1AHDAC1NPSR1SCN9ALMNA
SCHEMBL2715796 0.83 HDAC1 (0.42) ALDH1A1KDM1AHDAC1ROS1LMNA
SCHEMBL2713652 0.83 NR3C2 (0.53) KDM1AHDAC1ROS1LMNAHTT
SCHEMBL18266202 0.83 TACR1 (0.48) MLYCDHPGDALDH1A1KDM4ECYP1A2
SCHEMBL2718344 0.83 NAMPT (0.51) MLYCDHPGDALDH1A1KDM4ECYP1A2
SCHEMBL2716340 0.82 EPHX2 (0.47) KDM1AHDAC1ROS1SCN9ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2630122-B1 ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC (JP) 2016-11-30 EP claimed
US-9302991-B2 Arylamide derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2016-04-05 US claimed
US-20140336377-A1 ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2014-11-13 US claimed
EP-2630122-A1 ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS RaQualia Pharma Inc (JP) 2013-08-28 EP claimed
WO-2012053186-A1 ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2012-04-26 WO claimed
CN-106478497-B Arylamine derivatives as TTX-S blockers 拉夸里亚创药株式会社 2020-05-08 CN disclosed
EP-2630122-B1 ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC (JP) 2016-11-30 EP disclosed
US-9302991-B2 Arylamide derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2016-04-05 US disclosed
US-20140336377-A1 ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2014-11-13 US disclosed
US-20140336377-A1 ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2014-11-13 US disclosed
EP-2630122-A1 ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS RaQualia Pharma Inc (JP) 2013-08-28 EP disclosed
WO-2012053186-A1 ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2012-04-26 WO disclosed
WO-2012053186-A1 ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2012-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140336377-A1 ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS SCN2B, SCN1B, SCN2A MLYCD 4116/4885HPGD 1404/4885ALDH1A1 1358/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.